Evidence map›Paper›PMID 36792077›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2023

[Advances in the Study of Invasive Non-mucinous Adenocarcinoma 
with Different Pathological Subtypes].

Ruke Tang, Lina Bi, Bingquan Xiang, Lianhua Ye, Ying Chen, Guangjian Li, Guangqiang Zhao, Yunchao Huang

Open access · greenAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ruke TangDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Lina BiDepartment of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
Bingquan XiangDepartment of Intensive Care Unit, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Lianhua YeDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Ying ChenDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Guangjian LiDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Guangqiang ZhaoDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Yunchao HuangDepartment of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer death in the world today, and adenocarcinoma is the most common histopathological type of lung cancer. In May 2021, World Health Organization (WHO) released the 5th edition of the WHO classification of thoracic tumors, which classifies invasive non-mucinous adenocarcinoma (INMA) into lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, solid adenocarcinoma, and micropapillary adenocarcinoma based on its histological characteristics. These five pathological subtypes differ in clinical features, treatment and prognosis. A complete understanding of the characteristics of these subtypes is essential for the clinical diagnosis, treatment options, and prognosis predictions of patients with lung adenocarcinoma, including recurrence and progression. This article will review the grading system, morphology, imaging prediction, lymph node metastasis, surgery, chemotherapy, targeted therapy and immunotherapy of different pathological subtypes of INMA.
.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsHumansLymphatic MetastasisNeoplasm StagingPrognosisRetrospective StudiesInvasive adenocarcinomaInvasive non-mucinous adenocarcinomaLung neoplasmsPathological subtypes

Identifiers

PMID36792077
PMCPMC9987059
OpenAlexW4321003977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.